TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22800352
Drug: Anti-acid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-acid therapy and conventional pharyngo-laryngitis therapy in control group
Study: 20394491
Drug: Pimecrolimus cream
Normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimecrolimus cream 1% combined with fluticasone
Study: 18759257
Drug: Infliximab 5
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 5 mg/kg (group 2)
Study: 18759257
Drug: Placebo followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo followed by infliximab 5 mg/kg (group 1)
Study: 15897310
Drug: Placebo (sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sham ultrasound and non-therapeutic gel)
Study: 8592224
Drug: Tirilazad mesylate
Normalized name: tirilazad mesylate
DrugBank: Tirilazad (DB13050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirilazad mesylate 6 mg/kg per day
Study: 8592224
Drug: Tirilazad mesylate
Normalized name: tirilazad mesylate
DrugBank: Tirilazad (DB13050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirilazad mesylate 0.6 mg/kg per day
Study: 8592224
Drug: Tirilazad mesylate
Normalized name: tirilazad mesylate
DrugBank: Tirilazad (DB13050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirilazad mesylate 2 mg/kg per day
Study: 1868479
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment alone for reflux grade III or less
Study: 1868479
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment alone for reflux grade IV (control group)
Study: 6202972
Drug: Aspirin, 300
Normalized name: Aspirin, 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, 300 mg three times a day for 7 days
Study: 30614823
Drug: Ticagrelor 180
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 180 mg loading, followed by 90 mg twice daily
Study: 17763834
Drug: Prophylactic anticonvulsants
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic anticonvulsants
Study: 17763834
Drug: Seizure prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seizure prophylaxis with antiepileptic drugs
Study: 17763834
Drug: Literature on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Literature on prophylactic anticonvulsants
Study: 11232739
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care programme
Study: 11232739
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no pharmaceutical care)
Study: 9288859
Drug: 5‐ASA (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐ASA (4 g/day Pentasa)
Study: 3471376
Drug: Weekly 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly 0.2% neutral NaF rinse
Study: 30954486
Drug: Uric acid
Normalized name: Uric acid
DrugBank: Uric acid (DB08844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uric acid (UA) treatment (16 mg/kg)
Study: 21371292
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of ASA (stopping ASA five days prior to surgery and starting on postoperative day 5)
Study: 2574050
Drug: Sufotidine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufotidine 600 mg once daily
Study: 2574050
Drug: Sufotidine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufotidine 600 mg twice daily
Study: 23793032
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving weekly reminders to continue their usual physical activities
Study: 19533164
Drug: Upper limb
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upper limb resistance training (RT) at 80% of one repetition maximum, twice each week for 10 weeks
Study: 19533164
Drug: Lower limb
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower limb resistance training (RT) at 80% of one repetition maximum, twice each week for 10 weeks
Study: 16709552
Drug: Olanzapine (5-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5-15 mg/d)
Study: 9407756
Drug: Naproxen granular
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen granular 500 mg
Study: 8505452
Drug: Carbamide peroxide
Normalized name: Carbamide Peroxide
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamide peroxide gel
Study: 3429683
Drug: Prazosin (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (twice daily for eight weeks)
Study: 3429683
Drug: Prazosin (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (once daily for eight weeks)
Study: 30839494
Drug: Topical interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical interferon α2b 1 MU/mL
Study: 23264335
Drug: Multimodal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal therapy (MM)
Study: 16880100
Drug: PB127 (0.175
Approvals — FDA: no, EMA: no, PMDA: no
Description: PB127 (0.175 mg/kg diluted in 5% dextrose)
Study: 16880100
Drug: Dipyridamole (0.56
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (0.56 mg/kg)
Study: 10848655
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.d., clarithromycin 250 mg b.d., tinidazole 500 mg b.d. for 7 days (OCT)
Study: 23090499
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with all-trans retinoic acid and TAD (6-thioguanine, cytarabine, daunorubicin)
Study: 23090499
Drug: TAD-HAM induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAD-HAM induction (high dose cytarabine, mitoxantrone)
Study: 17961576
Drug: Soy supplementation
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy supplementation (52 g of soy protein containing 112 mg of isoflavones) for 8 weeks
Study: 17132972
Drug: Tramiprosate (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramiprosate (50, 100, or 150 mg twice daily for 12 weeks)
Study: 14630680
Drug: Chemotherapy (more
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (more intensive in GELA group)
Study: 14630680
Drug: Surgical resection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical resection plus chemotherapy (GELD group)
Study: 14630680
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (GELA group)
Study: 12835883
Drug: Sucralfate 3
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate 3 g in 15 ml suspension enema
Study: 12835883
Drug: Mesalazine 4
Normalized name: Mesalazine 400 mg gastro-resistant and prolonged-release oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine 4 g gel enema
Study: 12835883
Drug: Hydrocortisone 100
Normalized name: hydrocortisone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 100 mg foam enema
Study: 10389782
Drug: midazolam 0.5
Normalized name: midazolam 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam 0.5 mg/kg
Study: 8540847
Drug: Foscarnet sodium
Normalized name: Foscarnet Sodium
DrugBank: Foscarnet (DB00529)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Foscarnet sodium at 90 mg/kg intravenously every 12 hours for 2 weeks, followed by maintenance at 120 mg/kg per day
Study: 8540847
Drug: Ganciclovir sodium
Normalized name: Ganciclovir Sodium
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganciclovir sodium at 5 mg/kg intravenously every 12 hours for 2 weeks followed by maintenance at 10 mg/kg per day
Study: 8540847
Drug: Combination therapy:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy: induction with the other drug for 2 weeks followed by maintenance therapy with both drugs (ganciclovir at 5 mg/kg per day and foscarnet at 90 mg/kg per day)
Study: 1902405
Drug: Combination thrombolytic
Normalized name: THROMBOLYTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination thrombolytic therapy (both t-PA and urokinase)
Study: 25444793
Drug: Intramuscular bivalent
Normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular bivalent norovirus virus-like particle (VLP) vaccine (5 μg, 15 μg, 50 μg, and 150 μg doses)
Study: 25444793
Drug: Intramuscular bivalent
Normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular bivalent norovirus virus-like particle (VLP) vaccine
Study: 21663486
Drug: Bifidobacterium lactis
Normalized name: bifidobacterium lactis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium lactis HN019 high dose (17.2 billion CFU)
Study: 21663486
Drug: Bifidobacterium lactis
Normalized name: bifidobacterium lactis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium lactis HN019 low dose (1.8 billion CFU)
Study: 17238412
Drug: Propbank-based Machine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propbank-based Machine Learning (ML) for annotating abstracts of Randomized Controlled Trials
Study: 9024371
Drug: Intravenous salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous salbutamol (15 micrograms/kg)
Study: 9024371
Drug: Control (nebulised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (nebulised salbutamol at 2.5 mg or 5.0 mg, depending on age)
Study: 8295467
Drug: Active laser
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active laser treatment (1.2 J/point)
Study: 8295467
Drug: Inactive laser
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive laser treatment (0 J/point)
Study: 2950179
Drug: Sunscreen agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunscreen agent
Study: 2950179
Drug: Base used
Approvals — FDA: no, EMA: no, PMDA: no
Description: Base used in sunscreen preparation
Study: 20674829
Drug: Combination azelastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination azelastine and fluticasone nasal spray
Study: 14522298
Drug: Bupivacaine 0.75%
Normalized name: BUPivacaine 0.75% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.75% applied in 0.1 mL drops 3 times in the 30 minutes before surgery
Study: 14522298
Drug: Bupivacaine 0.75%
Normalized name: BUPivacaine 0.75% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.75% applied in 0.1 mL drops 6 times in the 60 minutes before surgery
Study: 9739895
Drug: Pristinamycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pristinamycin (1 g b.i.d. for 10 days)
Study: 9739895
Drug: Oxacillin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxacillin (1 g b.i.d. for 10 days)
Study: 3516619
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with azathioprin and steroids (Group A)
Study: 3516619
Drug: Antilymphocyte globulin
Normalized name: antilymphocyte immunoglobulin
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antilymphocyte globulin (ALG) for three weeks plus azathioprin and steroids (Group B)
Study: 3516619
Drug: ALG-azathioprin-steroid administration
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ALG-azathioprin-steroid administration for a mean of nine days followed by ciclosporin (Group C)
Study: 29165732
Drug: Melatonin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (20 mg/d)
Study: 16510862
Drug: Intensified, multicomponent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified, multicomponent geriatric treatment
Study: 11529973
Drug: sequential methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: sequential methotrexate and 5-fluorouracil (MF)
Study: 9088820
Drug: Post-operative oral
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative oral diazepam
Study: 8225043
Drug: Tocolytic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocolytic and antibiotic therapy
Study: 31447072
Drug: AVF surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVF surgical creation with placement of the VasQ implant
Study: 31447072
Drug: AVF surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVF surgical creation without the implant (control)
Study: 25225151
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Boswellia serrata L. and Cyperus scariosus L. (2g) plus pelvic floor muscle training
Study: 21887727
Drug: Adalimumab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (both dosing regimens)
Study: 20134178
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg ropivacaine with 20 microg fentanyl
Study: 20134178
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg hyperbaric bupivacaine with 20 microg fentanyl
Study: 16973987
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of montelukast and salmeterol
Study: 12225329
Drug: Histamine dihydrochloride
Normalized name: Histamine dihydrochloride
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Histamine dihydrochloride (HDC) in combination with IFN-alpha-2b, 3 MIU, three times weekly via subcutaneous injection, with HDC doses of 1 mg either once a day, three times a week; once a day, five times a week; twice a day, three times a week; or twice a day, five times a week.
Study: 9799034
Drug: Captopril (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (100 mg daily for 6 months)
Study: 9799034
Drug: Doxazosin (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (9 mg daily for 6 months)
Study: 1989962
Drug: Monthly written
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly written reports
Study: 21544071
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg for 7 days)
Study: 21544071
Drug: Bupropion (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (150 mg for 7 days)
Study: 17702699
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba treatment (240 mg daily) during the first 12 weeks and supervised exercise training during the second 12 weeks
Study: 17702699
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment during the first 12 weeks and supervised exercise training during the second 12 weeks
Study: 11723262
Drug: Zonisamide 400
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Zonisamide 400 mg/d
Study: 11723262
Drug: Zonisamide 100
Normalized name: zonisamide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zonisamide 100 mg/d
Study: 11723262
Drug: Zonisamide 200
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Zonisamide 200 mg/d
Study: 9160129
Drug: Ketorolac 30
Normalized name: ketorolac 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 30 mg IM every 8 hours
Study: 9160129
Drug: Metamizol 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metamizol 2 g IM every 8 hours
Study: 19819436
Drug: High-isoflavone soy
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-isoflavone soy protein isolate (high-iso SPI; 61.7 ± 7.35 mg isoflavones/day)
Study: 19819436
Drug: Low-isoflavone soy
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-isoflavone soy protein isolate (low-iso SPI; 1.64 ± 0.19 mg isoflavones/day)
Study: 15644045
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 9 MU interferon-alpha2a followed by weekly administration of 180 mug of pegylated interferon-alpha2a/ribavirin for 48 weeks
Study: 15644045
Drug: Weekly administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly administration of 180 mug of pegylated interferon-alpha2a/ribavirin for 48 weeks
Study: 12574761
Drug: Vestibular rehabilitation
Normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vestibular rehabilitation home program (specific details on dosage and duration not provided)
Study: 8762852
Drug: Detection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of anti-mycobacterial antibodies
Study: 8762852
Drug: Detection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of IgG or anti-mycobacterial antibodies or both
Study: 8762852
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of IgG or anti-mycobacterial antibodies in other cases
Study: 22250993
Drug: Lanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanthanum carbonate (LC), 3000 mg/day of elemental lanthanum
Study: 16222899
Drug: Telmisartan 40
Normalized name: telmisartan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 40 mg force-titrated to 80 mg after 1 month (n = 25)
Study: 16222899
Drug: Ramipril 2.5
Normalized name: ramipril 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 2.5 mg force-titrated to 5 mg after 1 month (n = 25)
Study: 16222899
Drug: Telmisartan 40
Normalized name: telmisartan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 40 mg plus Ramipril 2.5 mg (n = 25)
Study: 2676910
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg per day cyclosporin A (CsA)
Study: 799997
Drug: Cephradine (25-110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephradine (25-110 mg/kg per day) for 5-15 days
Study: 799997
Drug: Cephalexin (25-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin (25-150 mg/kg per day) for 5-15 days
Study: 29880175
Drug: 1700 mg
Normalized name: inulin 1700 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1700 mg metformin
Study: 19794198
Drug: Optimised care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimised care model with training on diagnosis and treatment of anxiety disorders and psychiatric consultation-liaison service for 6 months
Study: 12544454
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg indapamide SR
Study: 10839487
Drug: Cefdinir 600
Normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefdinir 600 mg once daily (OD)
Study: 10839487
Drug: Cefdinir 300
Normalized name: cefdinir 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefdinir 300 mg every 12 hours (BD)
Study: 10839487
Drug: Amoxicillin/clavulanate 500/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate 500/125 mg every 8 hours
Study: 8939177
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium 4 mg, given four times daily for 16 weeks
Study: 8939177
Drug: Albuterol 200
Normalized name: ALBUTEROL 200MCG CAP,INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol 200 micrograms, given four times daily for 16 weeks
Study: 17021584
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BT‐A) injection at gastrocnemius
Study: 17021584
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BT‐A) injection at adductors
Study: 17021584
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BT‐A) injection at gastrocnemius and adductors
Study: 16164922
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor (AI) formestane
Study: 16164922
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no aromatase inhibitor)
Study: 16164922
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antibodies)
Study: 12450691
Drug: Three injections
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three injections of BCG
Study: 10225312
Drug: Intra-oesophageal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-oesophageal lidocaine 20 mg/ml
Study: 25937443
Drug: Desmoteplase (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmoteplase (90 μg/kg) given 3-9 h after symptom onset
Study: 21056069
Drug: Soluble fiber
Normalized name: Soluble fiber
DrugBank: Methylcellulose (DB11228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble fiber dextrin (12 g)
Study: 21056069
Drug: Soluble corn
Normalized name: soluble corn fiber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble corn fiber (11.8 g)
Study: 21056069
Drug: Polydextrose (11.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polydextrose (11.8 g)
Study: 21056069
Drug: Resistant starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant starch (11.2 g)
Study: 19277873
Drug: Stress management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress management therapy (20 sessions of 2 hours each) and usual health care by a cardiologist
Study: 15327428
Drug: r‐halphaGalA (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐halphaGalA (1 mg/kg body weight continuously infused over 4 hours) during dialysis